These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism. Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674 [TBL] [Abstract][Full Text] [Related]
5. Medication mismanagement using the rivaroxaban demonstration pack. Nguyen TT; MacLasco A; Vitto MJ Am J Health Syst Pharm; 2017 Jun; 74(12):872-873. PubMed ID: 28596224 [No Abstract] [Full Text] [Related]
6. Heavy menstrual bleeding on rivaroxaban. Ferreira M; Barsam S; Patel JP; Czuprynska J; Roberts LN; Patel RK; Arya R Br J Haematol; 2016 Apr; 173(2):314-5. PubMed ID: 26212626 [No Abstract] [Full Text] [Related]
7. A Case Report of Henoch-Schonlein Purpura and IgA Nephropathy Associated With Rivaroxaban. Chung EY; Chen J; Roxburgh S Nephrology (Carlton); 2018 Mar; 23(3):289-290. PubMed ID: 29461002 [No Abstract] [Full Text] [Related]
8. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients. Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320 [TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban-induced liver injury: Results from a venous thromboembolism registry. Lambert A; Cordeanu M; Gaertner S; Nouri S; Alt M; Stephan D Int J Cardiol; 2015 Jul; 191():265-6. PubMed ID: 25981364 [No Abstract] [Full Text] [Related]
11. Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism? Vavlukis M; Kotlar I; Taravari H; Poposka L; Kedev S Anatol J Cardiol; 2017 Jul; 18(1):77-79. PubMed ID: 28680014 [No Abstract] [Full Text] [Related]
12. Acute cytomegalovirus infection associated with pulmonary embolism treated successfully with rivaroxaban: case report. de Almeida CMG; Maluf FC; Maluf FC; Gaburo N; Saraceni AF; de Almeida-Neto C J Thromb Thrombolysis; 2019 Jan; 47(1):162-164. PubMed ID: 30353451 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Coleman CI; Bunz TJ; Turpie AGG Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322 [TBL] [Abstract][Full Text] [Related]
14. Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. Weeda ER; Wells PS; Peacock WF; Fermann GJ; Baugh CW; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI Int J Cardiol; 2016 Nov; 222():846-849. PubMed ID: 27522388 [No Abstract] [Full Text] [Related]
15. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER). Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301 [TBL] [Abstract][Full Text] [Related]